TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma

被引：0
|
作者：
Kaifeng, J. [1 ]
Zewei, W. [1 ]
Zhaopei, L. [2 ]
Jiejie, X. [3 ]
机构：
[1] Fudan Univ, Dept Urol, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Biochem & Mol Biol, Shanghai, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0757
引用
收藏
页码：S1737 / S1738
页数：2
相关论文
共 50 条
  • [41] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [42] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
  • [43] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
  • [44] TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas
    Alos, Llucia
    Fuster, Carla
    Castillo, Paola
    Jares, Pedro
    Garcia-Herrera, Adriana
    Marginet, Marta
    Agreda, Fernando
    Arance, Ana
    Gonzalvo, Elena
    Garcia, Mireia
    Puig, Susana
    Teixido, Cristina
    ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (19)
  • [45] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
    Meghan M. Lynch
    Borislav A. Alexiev
    Brett A. Schroeder
    Seth M. Pollack
    Current Treatment Options in Oncology, 2022, 23 : 1861 - 1876
  • [46] Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma
    Park, Kye Jin
    Lee, Jae-Lyun
    Yoon, Shin-Kyo
    Heo, Changhoe
    Park, Bum Woo
    Kim, Jeong Kon
    EUROPEAN RADIOLOGY, 2020, 30 (10) : 5392 - 5403
  • [47] Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma
    Kye Jin Park
    Jae-Lyun Lee
    Shin-Kyo Yoon
    Changhoe Heo
    Bum Woo Park
    Jeong Kon Kim
    European Radiology, 2020, 30 : 5392 - 5403
  • [48] Combinations of Chemotherapy and PD-1/PD-L1 Inhibitors in Sarcoma
    Lynch, Meghan M.
    Alexiev, Borislav A.
    Schroeder, Brett A.
    Pollack, Seth M.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1861 - 1876
  • [49] Platinum-Based Chemotherapy is Associated with Altered PD-L1 Expression in Lung Cancer
    Moldyay, J.
    Rojko, L.
    Teglasi, V.
    Fabian, K.
    Pipek, O.
    Vagyolgyi, A.
    Agocs, L.
    Fillinger, J.
    Kajdacsi, Z.
    Timar, J.
    Dome, B.
    Szallasi, Z.
    Reiniger, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S733 - S733
  • [50] PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma
    B Paiva
    A Azpilikueta
    N Puig
    E M Ocio
    R Sharma
    B O Oyajobi
    S Labiano
    L San-Segundo
    A Rodriguez
    I Aires-Mejia
    I Rodriguez
    F Escalante
    A G de Coca
    A Barez
    J F San Miguel
    I Melero
    Leukemia, 2015, 29 : 2110 - 2113
12345